{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:44:38Z","timestamp":1794008678572,"version":"4.8.0"},"reference-count":54,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Cervical cancer remains a major public health concern, particularly in low- and middle-income countries (LMICs) where access to preventive measures is limited. Persistent infection with high-risk human papillomavirus (HPV) types, mainly HPV16 and HPV18, is the key cause of cervical cancer. While prophylactic HPV vaccines effectively prevent new infections, they offer no therapeutic benefit for individuals with established lesions. This review evaluates the clinical evidence on therapeutic HPV vaccines, focusing on their ability to promote viral clearance. A bibliographic search was conducted in PubMed, selecting human studies reporting outcomes on HPV clearance. Seventeen clinical trials were identified, including DNA-based (VGX-3100, GX-188E), viral-vector (MVA E2, TG4001), peptide-based (Pepcan), and bacterial-vector (GLT 001) vaccines. Among them, DNA-based vaccines, particularly VGX-3100, showed the most consistent results, whereas several protein- or vector-based approaches demonstrated variable outcomes. Early therapeutic HPV vaccine trials faced setbacks due to limited efficacy, delivery approaches, and study design challenges, preventing progression to late-phase development. Recent DNA-based candidates, however, are advancing through phase II\/III trials. While none have yet to be approved for commercial use, these vaccines elicit virus-specific T-cell responses and can induce regression of precancerous lesions, offering a promising addition to prophylactic vaccination and screening. Variability in study designs and endpoints underlines the need for standardized protocols and further phase III trials. Overall, therapeutic HPV vaccines represent a rapidly advancing field with the potential to complement prophylactic vaccination and screening, thereby strengthening global cervical cancer control efforts, particularly in LMICs.<\/jats:p>","DOI":"10.3390\/curroncol32110600","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:48:46Z","timestamp":1761716926000},"page":"600","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials"],"prefix":"10.3390","volume":"32","author":[{"given":"Elena","family":"Mart\u00edn","sequence":"first","affiliation":[{"name":"School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4079-9753","authenticated-orcid":false,"given":"Gabriel","family":"Reina","sequence":"additional","affiliation":[{"name":"Microbiology Department, Cl\u00ednica Universidad de Navarra, 31008 Pamplona, Spain"},{"name":"IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4968-7080","authenticated-orcid":false,"given":"Silvia","family":"Carlos","sequence":"additional","affiliation":[{"name":"IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain"},{"name":"Department of Preventive Medicine and Public Health, Universidad de Navarra, 31008 Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, August 01). Cervical Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3892\/ol.2020.11754","article-title":"Cervical cancer in low and middle-income countries","volume":"20","author":"Hull","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_4","first-page":"20","article-title":"Chapter 3: Cofactors in Human Papillomavirus Carcinogenesis\u2014Role of Parity, Oral Contraceptives, and Tobacco Smoking","volume":"31","year":"2003","journal-title":"JNCI Monogr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/rmv.488","article-title":"Human papillomaviruses: Basic mechanisms of pathogenesis and oncogenicity","volume":"16","author":"Hebner","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"ref_6","unstructured":"World Health Organization (WHO) (2025, August 01). Preferred Product Characteristics for Therapeutic Human Papillomavirus Vaccines, Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240092174."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","article-title":"Human Papillomavirus and Cervical Cancer","volume":"16","author":"Burd","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200313","DOI":"10.1016\/j.tvr.2025.200313","article-title":"How Can HPV E6 Manipulate the Host Cell Differentiation Process to Maintain the Reservoir of Infection?","volume":"19","author":"Chen","year":"2025","journal-title":"Tumour Virus Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1158\/0008-5472.CAN-06-0630","article-title":"Prospects for Cervical Cancer Prevention by Human Papillomavirus Vaccination","volume":"66","author":"Schiller","year":"2006","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bowden, S.J., Doulgeraki, T., Bouras, E., Markozannes, G., Athanasiou, A., Grout-Smith, H., Kechagias, K.S., Ellis, L.B., Zuber, V., and Chadeau-Hyam, M. (2023). Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: An umbrella review and follow-up Mendelian randomisation studies. BMC Med., 21.","DOI":"10.1186\/s12916-023-02965-w"},{"key":"ref_11","unstructured":"(2025, August 01). About Genital HPV Infection|STI|CDC, Available online: https:\/\/www.cdc.gov\/sti\/about\/about-genital-hpv-infection.html."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1042\/CS20160786","article-title":"The human papillomavirus replication cycle, and its links to cancer progression: A comprehensive review","volume":"131","author":"Graham","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"200238","DOI":"10.1016\/j.tvr.2022.200238","article-title":"Cervical cancer therapies: Current challenges and future perspectives","volume":"13","author":"Burmeister","year":"2022","journal-title":"Tumour Virus Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sun, Q., Wang, L., Zhang, C., Hong, Z., and Han, Z. (2022). Cervical cancer heterogeneity: A constant battle against viruses and drugs. Biomark. Res., 10.","DOI":"10.1186\/s40364-022-00428-7"},{"key":"ref_15","unstructured":"(2025, August 01). World Health Organisation (WHO): Cervical Cancer Elimination Initiative. Available online: https:\/\/www.who.int\/initiatives\/cervical-cancer-elimination-initiative."},{"key":"ref_16","unstructured":"(2025, August 01). CDC Primary Prevention Methods, Available online: https:\/\/www.cdc.gov\/std\/treatment-guidelines\/clinical-primary.htm."},{"key":"ref_17","unstructured":"(2025, August 01). Sexually Transmitted Infections (STIs). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexually-transmitted-infections-(stis)."},{"key":"ref_18","unstructured":"(2025, August 01). Global Sexually Transmitted Infections Programme. Available online: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/stis\/prevention."},{"key":"ref_19","unstructured":"St. Jude Childrens Research Hospital (2025, August 01). History of HPV Vaccination. Available online: https:\/\/sjr-redesign.stjude.org\/content\/dam\/research-redesign\/centers-initiatives\/hpv-cancer-prevention-program\/hpv-advocacy-campaign\/history-hpv-vaccination.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jncimonographs\/lgae026","article-title":"Human papillomavirus prophylactic vaccines: Update on new vaccine development and implications for single-dose policy","volume":"67","author":"Schuind","year":"2024","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kutz, J.M., Rausche, P., Gheit, T., Puradiredja, D.I., and Fusco, D. (2023). Barriers and facilitators of HPV vaccination in sub-saharan Africa: A systematic review. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-15842-1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1001\/jama.2023.21987","article-title":"Cervical Cancer Screening","volume":"330","author":"Voelker","year":"2023","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_24","unstructured":"(2025, August 01). Papilocare Gel Vaginal\u2014Papilocare. Available online: https:\/\/papilocare.com\/papilocare-gel-vaginal\/."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/LGT.0000000000000596","article-title":"Efficacy of a Coriolus versicolor-Based Vaginal Gel in Women with Human Papillomavirus-Dependent Cervical Lesions: The PALOMA Study","volume":"25","author":"Serrano","year":"2021","journal-title":"J. Low. Genit. Tract Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"F71","DOI":"10.1016\/j.vaccine.2012.05.091","article-title":"Therapy of Human Papillomavirus-Related Disease","volume":"30","author":"Stern","year":"2012","journal-title":"Vaccine"},{"key":"ref_27","unstructured":"(2025, August 01). Cervical Cancer Treatment\u2014NCI, Available online: https:\/\/www.cancer.gov\/types\/cervical\/treatment."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00109-022-02199-y","article-title":"Current and future direction in treatment of HPV-related cervical disease","volume":"100","author":"Khairkhah","year":"2022","journal-title":"J. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101224","DOI":"10.1016\/j.mam.2023.101224","article-title":"Vaccines for HPV-associated diseases","volume":"94","author":"Skolnik","year":"2023","journal-title":"Mol. Asp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Beyaert, S., Machiels, J.P., and Schmitz, S. (2021). Vaccine-Based Immunotherapy for Head and Neck Cancers. Cancers, 13.","DOI":"10.3390\/cancers13236041"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/hum.2017.197","article-title":"Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases","volume":"29","author":"Cheng","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"105747","DOI":"10.1016\/j.micpath.2022.105747","article-title":"Combination therapy between prophylactic and therapeutic human papillomavirus (HPV) vaccines with special emphasis on implementation of nanotechnology","volume":"171","author":"Gohar","year":"2022","journal-title":"Microb. Pathog."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: A randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1038\/ncomms6317","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3","volume":"26","author":"Choi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/10430340460745757","article-title":"Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus","volume":"15","author":"Gutierrez","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Contreras","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1158\/1078-0432.CCR-16-0085","article-title":"GTL001, a therapeutic vaccine for women infected with human papillomavirus 16 or 18 and normal cervical cytology: Results of a phase I clinical trial","volume":"22","author":"Hens","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_40","unstructured":"(2025, August 01). Genticel Reports Final Results of GTL001 Phase 2 Trial in HPV16\/18-Infected Women. Available online: https:\/\/www.globenewswire.com\/news-release\/2016\/12\/13\/897347\/0\/en\/Genticel-Reports-Final-Results-of-GTL001-Phase-2-Trial-in-HPV16-18-Infected-Women.html."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","author":"Brun","year":"2011","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ygyno.2019.03.250","article-title":"The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up","volume":"153","author":"Harper","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1031439","DOI":"10.1080\/2162402X.2015.1031439","article-title":"A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2\/3","volume":"4","author":"Greenfield","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-016-1821-x","article-title":"Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination","volume":"65","author":"Coleman","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1158\/1078-0432.CCR-24-1662","article-title":"Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial","volume":"31","author":"Eerkens","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.AOG.0000110246.93627.17","article-title":"ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: A randomized controlled trial","volume":"103","author":"Garcia","year":"2004","journal-title":"Obstet. Gynecol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2007.04.038","article-title":"Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III","volume":"106","author":"Einstein","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2007.05.038","article-title":"A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia","volume":"106","author":"Roman","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_49","first-page":"292951","article-title":"Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial","volume":"2011","author":"Solares","year":"2011","journal-title":"ISRN Obs. Gynecol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"pkad101","DOI":"10.1093\/jncics\/pkad101","article-title":"Phase I and II randomized clinical trial of an oral therapeutic vaccine targeting human papillomavirus for treatment of cervical intraepithelial neoplasia 2 and 3","volume":"7","author":"Kawana","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"ref_51","unstructured":"Inovio Pharmaceuticals Inc. (2025, August 01). INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, Its DNA-Based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and\/or HPV-18. Available online: https:\/\/ir.inovio.com\/news-releases\/news-releases-details\/2021\/INOVIO-Highlights-Key-Updates-on-Phase-3-Program-for-VGX-3100-its-DNA-based-Immunotherapy-for-the-Treatment-of-Cervical-HSIL-Caused-by-HPV-16-andor-HPV-18\/default.aspx."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e069616","DOI":"10.1136\/bmjopen-2022-069616","article-title":"Efficacy and Safety of Therapeutic HPV Vaccines to Treat CIN2\/CIN3 Lesions: A Systematic Review and Meta-Analysis of Phase II\/III Clinical Trials","volume":"13","author":"Khalil","year":"2023","journal-title":"BMJ Open"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pvr.2019.04.010","article-title":"Opportunities to improve immune-based prevention of HPV-associated cancers","volume":"7","author":"Stern","year":"2019","journal-title":"Papillomavirus Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wang, R., Huang, H., Yu, C., Li, X., Wang, Y., and Xie, L. (2024). Current Status and Future Directions for the Development of Human Papillomavirus Vaccines. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1362770"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/600\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:52:27Z","timestamp":1761720747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["curroncol32110600"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32110600","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]}}}